A registry following adults with lupus in Pakistan
Collects health information from adults with systemic lupus erythematosus in Pakistan.
Plain-language title generated from the registry record
Registry title: Pakistan Arthritis and Connective Tissue Disease Network - Systemic Lupus Erythematosus
Key facts
- Where
- Rawalpindi, PakistanSee the site
Where in Pakistan
- Fauji Foundation Hospital, RawalpindiRawalpindi, PakistanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Foundation University Islamabad
- Trial code
- NCT07902622
- Record updated
- 29 October 2026
- Original description
Systemic lupus erythematosus (SLE) is a complex autoimmune disorder that affects individuals globally, yet there is a significant lack of data regarding its prevalence and management, particularly in Asian populations like Pakistan. To address this gap, we are initiating a groundbreaking project to establish a Lupus Registry in Pakistan.Read full original descriptionShow less
Pakistan Arthritis and Connective Tissue Disease Network - Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a complex autoimmune disorder that affects individuals globally, yet there is a significant lack of data regarding its prevalence and management, particularly in Asian populations like Pakistan. To address this gap, we are initiating a groundbreaking project to establish a Lupus Registry in Pakistan.
Our aim is to gain a better understanding of how SLE presents and progresses within the Pakistani population. By collecting detailed information on we hope to provide valuable insights that can tailor diagnostic and therapeutic approaches to suit the local context.
This project will enroll adult SLE patients initially from Fauji Foundation Hospital Rawalpindi, with plans to expand to other centers nationwide. Trained healthcare professionals will collect data through structured protocol as outlined in detailed project description. Through rigorous data collection and analysis, including the use of validated instruments and statistical methods, we aim to delineate clinical features, disease severity, treatment patterns, outcomes, and factors influencing these parameters. Ethical approval and informed consent will be obtained to ensure the protection of patients' rights and appropriate data usage.
This registry will be a crucial step toward addressing the unique challenges faced by SLE patients in our population. Through collaboration and data-driven insights, we hope to pave the way for more personalized and effective healthcare interventions in the future.
Inclusion: All patients presenting with SLE diagnosed by phyician and fulfilling SLICC2012 or EULAR/ACR2019 criteria.
Exclusion: SLE patient who defers informed consent.